[go: up one dir, main page]

BRPI0511435A - adam12, um novo marcador para função celular anormal - Google Patents

adam12, um novo marcador para função celular anormal

Info

Publication number
BRPI0511435A
BRPI0511435A BRPI0511435-7A BRPI0511435A BRPI0511435A BR PI0511435 A BRPI0511435 A BR PI0511435A BR PI0511435 A BRPI0511435 A BR PI0511435A BR PI0511435 A BRPI0511435 A BR PI0511435A
Authority
BR
Brazil
Prior art keywords
adam12
marker
function
assay
abnormal cellular
Prior art date
Application number
BRPI0511435-7A
Other languages
English (en)
Inventor
Ulla M Wewer
Michael Christiansen
Camilla Fr Lich
Jennie Laigaard
Bent Norgaard-Pedersen
Kevin Spencer
Original Assignee
Uinv Kobenhavns
Statens Seruminstitut
Harold Wood Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uinv Kobenhavns, Statens Seruminstitut, Harold Wood Hospital filed Critical Uinv Kobenhavns
Publication of BRPI0511435A publication Critical patent/BRPI0511435A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ADAM12, UM NOVO MARCADOR PARA FUNçãO CELULAR ANORMAL. A presente invenção proporciona um método, um ensaio e um kit para proporcionar uma indicação de função celular anormal. Foi visto surpreendentemente que a alteração na concentração sérica de ADAM12 nos indivíduos foi útil como uma ferramenta prognóstica para prever o resultado clínico, complicações e mortalidade seguintes a uma função celular anormal. Os presentes inventores descrevem ADAM12 como um marcador geral global para função celular anormal, e o presente inventor demonstra pela primeira vez que ADAM12 é um importante indicador de doença cromossómica fetal e função placentária. Especificamente ADAM12 é um bom marcador para, por exemplo, síndrome de Down, trissomia 18, pré-eclâmpsia, síndrome de Turner tanto no primeiro quanto no segundo trimestres. Os presentes inventores desenvolveram um ensaio imunossorvente ligado a enzima (ELISA) e um ensaio imunofluorométrico dependente de tempo (time-resolved para) a quantificação de ADAM12 no soro. O presente pedido demonstra em vários exemplos a variação do nível de ADAM12 em anormalidade fetal e/ou resultados adversos da gravidez correlacionados com a idade gestacional comparados com controles normais. E um objeto da invenção proporcionar um aprimoramento dos ensaios dos marcadores existentes que apresenta um índice falso positivo reduzido.
BRPI0511435-7A 2004-05-19 2005-05-18 adam12, um novo marcador para função celular anormal BRPI0511435A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57251904P 2004-05-19 2004-05-19
PCT/DK2005/000326 WO2005111626A2 (en) 2004-05-19 2005-05-18 Adam12, a novel marker for abnormal cell function

Publications (1)

Publication Number Publication Date
BRPI0511435A true BRPI0511435A (pt) 2007-12-26

Family

ID=34956324

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511435-7A BRPI0511435A (pt) 2004-05-19 2005-05-18 adam12, um novo marcador para função celular anormal

Country Status (11)

Country Link
US (3) US7678544B2 (pt)
EP (3) EP2175277B1 (pt)
CN (1) CN1981196B (pt)
AR (1) AR049279A1 (pt)
AT (1) ATE518142T1 (pt)
AU (1) AU2005243064A1 (pt)
BR (1) BRPI0511435A (pt)
CA (1) CA2508779A1 (pt)
DE (1) DE05739600T1 (pt)
MX (1) MXPA06013470A (pt)
WO (1) WO2005111626A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1524523A1 (en) * 2003-10-17 2005-04-20 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Use of ADAM 12 for diagnosis and therapy of preeclampsia
TWI367260B (en) * 2005-03-18 2012-07-01 Univ Hong Kong Chinese Method for detecting the presence of a fetus with trisomy 21 in a pregnant woman and kit thereof
AU2007210124A1 (en) * 2006-01-26 2007-08-09 The Trustees Of The University Of Pennsylvania Tumor vasculature markers and methods of use thereof
WO2008119882A2 (en) * 2007-03-30 2008-10-09 Wallac Oy Screening methods based on human adam12 polypeptide and binding agents thereof
KR20190030779A (ko) 2008-01-18 2019-03-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
CN104777307B (zh) * 2008-10-31 2019-10-18 耶鲁大学 先兆子痫检测和治疗的方法和组合物
US20110251094A1 (en) 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
WO2012012694A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
BR112013001752A2 (pt) 2010-07-23 2016-05-31 Harvard College método de detectar doenças ou condições usando células fagocídicas
CA2819886A1 (en) * 2010-12-06 2012-06-14 Pronota N.V. Biomarkers and parameters for hypertensive disorders of pregnancy
US8703128B2 (en) 2011-01-24 2014-04-22 New York University Methods of modulating TGFβ signaling
WO2013000992A1 (en) 2011-06-28 2013-01-03 Vitateq Biotechnology Gmbh Method for diagnosing preeclampsia
CA2886489A1 (en) * 2011-10-14 2013-04-18 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
CN103105384A (zh) * 2012-09-20 2013-05-15 河南生生医疗器械有限公司 一种时间分辨荧光法综合检测乳腺癌试剂盒及其应用
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
EP4513187A3 (en) 2013-03-09 2025-05-21 Immunis.AI, Inc. Methods of detecting prostate cancer
CA2907120C (en) * 2013-03-15 2023-10-17 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
CN107076752A (zh) * 2014-07-02 2017-08-18 曼普知识产权控股有限公司 检测异位妊娠的方法
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
RU2724013C2 (ru) * 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
WO2018076134A1 (en) * 2016-10-24 2018-05-03 Ldx Prognostics Limited Co. Methods and kits for providing a preeclampsia assessment and prognosing preterm birth
CN106771265A (zh) * 2017-01-12 2017-05-31 广州市丰华生物工程有限公司 生长激素定量检测试剂盒及其制备方法
CN109726391B (zh) * 2018-12-11 2024-01-09 中科恒运股份有限公司 对文本进行情感分类的方法、装置及终端
CN111047577B (zh) * 2019-12-12 2021-02-26 太原理工大学 一种畸形尿红细胞分类统计方法与系统
CN114958758B (zh) * 2021-02-18 2024-04-23 南京启真基因工程有限公司 一种乳腺癌模型猪的构建方法及应用
CN117954083B (zh) * 2023-03-01 2024-07-05 暨南大学附属第一医院（广州华侨医院） 一种基于机器学习算法的子痫前期预测方法
CN118178615B (zh) * 2024-03-27 2024-12-17 南方医科大学 趋化因子xcl1在制备抗高龄孕妇晚期不良妊娠结局药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1364772A (zh) * 2001-01-10 2002-08-21 上海博德基因开发有限公司 一种新的多肽——人驱动蛋白轻链 14.74和编码这种多肽的多核苷酸
EP1509596A1 (en) * 2002-04-19 2005-03-02 BioImage A/S Translocation dependent complementation for drug screening
EP1524523A1 (en) 2003-10-17 2005-04-20 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Use of ADAM 12 for diagnosis and therapy of preeclampsia

Also Published As

Publication number Publication date
MXPA06013470A (es) 2008-03-13
US7678544B2 (en) 2010-03-16
CN1981196B (zh) 2012-10-03
EP2175277B1 (en) 2013-09-04
AU2005243064A1 (en) 2005-11-24
ATE518142T1 (de) 2011-08-15
US8114609B2 (en) 2012-02-14
AR049279A1 (es) 2006-07-12
EP1901074B1 (en) 2011-07-27
US20120149040A1 (en) 2012-06-14
DE05739600T1 (de) 2006-12-28
CA2508779A1 (en) 2005-11-19
WO2005111626A3 (en) 2005-12-29
EP1687640A2 (en) 2006-08-09
EP1901074A1 (en) 2008-03-19
US20060134654A1 (en) 2006-06-22
US20100190174A1 (en) 2010-07-29
WO2005111626A2 (en) 2005-11-24
EP2175277A1 (en) 2010-04-14
CN1981196A (zh) 2007-06-13

Similar Documents

Publication Publication Date Title
BRPI0511435A (pt) adam12, um novo marcador para função celular anormal
Alfirevic et al. How strong is the association between maternal thrombophilia and adverse pregnancy outcome?: A systematic review
ES2955883T3 (es) Pares de biomarcadores para la predicción del parto prematuro
Khaliq et al. The role of uric acid in preeclampsia: is uric acid a causative factor or a sign of preeclampsia?
Serin et al. Predictive value of tumor necrosis factor alpha (TNF-α) in preeclampsia
Salahuddin et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy
Mecacci et al. Thyroid autoimmunity and its association with non-organ-specific antibodies and subclinical alterations of thyroid function in women with a history of pregnancy loss or preeclampsia
Winkler Blood coagulation and oral contraceptives: a critical review
Berks et al. Associations between phenotypes of preeclampsia and thrombophilia
McCowan et al. Inherited thrombophilias are not increased in “idiopathic” small-for-gestational-age pregnancies
Asiltas et al. Prediction of first-trimester preeclampsia: Relevance of the oxidative stress marker MDA in a combination model with PP-13, PAPP-A and beta-HCG
Mitriuc et al. The obstetric complications in women with hereditary thrombophilia
Daponte et al. Soluble FMS-like tyrosine kinase-1 (sFlt-1) and serum placental growth factor (PlGF) as biomarkers for ectopic pregnancy and missed abortion
Hyun et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation
Bennett et al. Women with unexplained recurrent pregnancy loss do not have evidence of an underlying prothrombotic state: experience with calibrated automated thrombography and rotational thromboelastometry
Tikkanen et al. Self-reported smoking habits and serum cotinine levels in women with placental abruption
Sachan et al. Diagnostic and prognostic significance of serum soluble endoglin levels in preeclampsia and eclampsia
Acharya et al. Prediction of preeclampsia-bench to bedside
Erez et al. Preeclampsia is associated with low concentrations of protein Z
Prasmusinto et al. Ethnic differences in the association of factor V Leiden mutation and the C677T methylenetetrahydrofolate reductase gene polymorphism with preeclampsia
Olsen et al. Correlation between spontaneous preterm birth and mid-trimester maternal serum estriol
Dhok et al. Biomarkers for prediction of preterm delivery: A hospital-based study
Coppens et al. Inherited thrombophilias
Qiao et al. Variant ATRX Syndrome with Dysfunction of ATRX and MAGT 1 Genes
Ganzevoort et al. Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]